Funder
SERVIER SPAIN FOR THE MEDICAL WRITING ASSISTANCE
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference45 articles.
1. Volpetti S, Zaja F, Fanin R (2014) Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. Onco Targets Ther 7:865–872.
https://doi.org/10.2147/OTT.S34055
2. Menna P, Salvatorelli E, Minotti G (2016) Rethinking drugs from chemistry to therapeutic opportunities: pixantrone beyond anthracyclines. Chem Res Toxicol 29(8):1270–1278.
https://doi.org/10.1021/acs.chemrestox.6b00190
3. European Medicines Agency (2012) Pixuvri (pixantrone): summary of product characteristics.
https://www.ema.europa.eu/en/documents/product-information/pixuvri-epar-product-information_en.pdf
. Accessed 20 August 2018
4. Beggiolin G, Crippa L, Menta E, Manzotti C, Cavalletti E, Pezzoni G, Torriani D, Randisi E, Cavagnoli R, Sala F, Giuliani FC, Spinelli S (2001) Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori 87(6):407–416.
https://doi.org/10.1177/030089160108700611
5. Cavalletti E, Crippa L, Mainardi P, Oggioni N, Cavagnoli R, Bellini O, Sala F (2007) Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Investig New Drugs 25(3):187–195.
https://doi.org/10.1007/s10637-007-9037-8
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献